| HOME >> MEDICINE >> TECHNOLOGY |
16.2 %15.4 %16.0 %15.4 %Operating income
18.6 %22.0 %19.2 %21.4 %Six Months EndedConsolidatedDecember 29, 2012December 31, 2011% ChangeGAAPNon-GAAP AdjustmentsAs AdjustedGAAPNon-GAAP AdjustmentsAs AdjustedGAAPAs AdjustedNet sales
$ 1,652,769$
-$ 1,652,769$ 1,563,465$
-$ 1,563,4656 %6 %Cost of sales
1,060,33536,632
(a,b)
1,023,7031,041,01155,292
(a,g)
985,7192 %4 %Gross profit
592,43436,632629,066522,45455,292577,74613 %9 %Operating expensesDistribution
22,466-22,46619,359-19,35916 %16 %Research and development
55,718-55,71850,786(3,500)
(h)
54,28610 %3 %Selling and administration
193,82014,851
(a,c,f)
178,969190,08919,049
(a,i)
171,0402 %5 %Total operating expenses
272,00414,851257,153260,23415,549244,6855 %5 %Operating income
320,43051,483371,913262,22070,841333,06122 %12 %Interest, net
31,167-31,16728,211-28,21110 %10 %Other expense, net
14-14981-981-99 %-99 %Loss on sale of investment
3,0493,049------Income before income taxes
286,20054,532340,732233,02870,841303,86923 %12 %Income tax expense
74,66518,515
(j)
93,18062,83125,288
(j)
88,11919 %6 %Net income
$
211,535$
36,017$
247,552$
70,197$
45,553$
215,75024 %15 %Diluted earnings per share
$
2.24$
2.62$
.81$
2.3024 %14 %Diluted weighted average shares outstanding
94,40894,40893,98393,983Selected ratios as a percentage of net salesGross profit
35.8 %38.1 %33.4 %37.0 %Operating expenses
16.5 %15.6 %16.6 %15.7 %Operating income
19.4 %22.5 %16.8 %21.3 %(a) Deal-related amortization(b) Inventory step-up of $7,693(c) Severance costs of $1,526(d) Acqu
'/>"/>
| SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved |